Skip to main content
. 2016 Oct 24;6:35854. doi: 10.1038/srep35854

Figure 1. Prognostic value of basal tumor cell isolation and patient-derived xenograft engraftment in clinical bladder cancers.

Figure 1

(A) Schematic for prospective collection of patient-derived bladder cancers at the University of Chicago Medical Center. (B) Distribution of bladder tumor differentiation states (n = 56) based on flow cytometric isolation of basal or triple positive (CD90+/CD44+/CD49f+), intermediate or double positive (CD90−/CD44+/CD49f+) and differentiated or single positive (CD90−/CD44−/CD49f+) bladder tumor cells. (C) Kaplan-Meier curves comparing overall survival for patients with basal and differentiated tumors in early stage ([pathologic] pT1-T2 and N0 [lymph node-negative]; n = 15) and locally advanced (pT3-T4 or N + [lymph node-positive]; n = 33) tumors. (D) Kaplan-Meier curves comparing overall survival for patients stratified by PDX engraftment in early stage and locally advanced tumors. BTC, basal tumor cell. PDX, patient-derived xenograft. Time to death was calculated as the interval between radical cystectomy and date of death or last follow-up. P-values were determined using log-rank tests.